Johnson & Johnson

11/22/2024 | Press release | Distributed by Public on 11/22/2024 07:02

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor